Quotient Limited Announces Receipt of the ISO 13485:2016 Certification of its State of the Art MosaiQ™ Microarray Manufacturing Facility

JERSEY, Channel Islands, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported receipt of the formal ISO 13485:2016 certification for its state of the art MosaiQ™ multiplexing microarray manufacturing facility following the successful conclusion of the related European regulatory audit in September of this year.

This manufacturing system approval is a critical step in the ongoing commercialization plans for the MosaiQ™ microarray technology which is designed to transform transfusion diagnostics and beyond. Following the recent CE marking of the MosaiQ™ instrument, this ISO certification represents the second of three critical approvals required for entry into the European transfusion diagnostics market. Following successful field trials earlier this year the Company also filed a CE mark submission for its initial Immunohematology (IH) microarray in September of 2018.

Franz Walt, Quotient’s Chief Executive Officer commented, “As a result of this important milestone, all future microarray development can now benefit both from the instrument CE mark and from the medical device specific ISO 13485:2016 certification of our high-volume microarray manufacturing facility.”

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The Company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ™ and other new products. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or worsening adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.